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BACKGROUND
Secukinumab is an anti–interleukin-17A monoclonal antibody that has been shown 
to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted 
two phase 3 trials of secukinumab in patients with active ankylosing spondylitis.
METHODS
In two double-blind trials, we randomly assigned patients to receive secukinumab or 
placebo. In MEASURE 1, a total of 371 patients received intravenous secukinumab 
(10 mg per kilogram of body weight) or matched placebo at weeks 0, 2, and 4, fol-
lowed by subcutaneous secukinumab (150 mg or 75 mg) or matched placebo every 
4 weeks starting at week 8. In MEASURE 2, a total of 219 patients received subcu-
taneous secukinumab (150 mg or 75 mg) or matched placebo at baseline; at weeks 
1, 2, and 3; and every 4 weeks starting at week 4. At week 16, patients in the pla-
cebo group were randomly reassigned to subcutaneous secukinumab at a dose of 
150 mg or 75 mg. The primary end point was the proportion of patients with at least 
20% improvement in Assessment of Spondyloarthritis International Society (ASAS20) 
response criteria at week 16.
RESULTS
In MEASURE 1, the ASAS20 response rates at week 16 were 61%, 60%, and 29% for 
subcutaneous secukinumab at doses of 150 mg and 75 mg and for placebo, respec-
tively (P<0.001 for both comparisons with placebo); in MEASURE 2, the rates were 
61%, 41%, and 28% for subcutaneous secukinumab at doses of 150 mg and 75 mg 
and for placebo, respectively (P<0.001 for the 150-mg dose and P = 0.10 for the 75-mg 
dose). The significant improvements were sustained through 52 weeks. Infections, 
including candidiasis, were more common with secukinumab than with placebo 
during the placebo-controlled period of MEASURE 1. During the entire treatment 
period, pooled exposure-adjusted incidence rates of grade 3 or 4 neutropenia, can-
dida infections, and Crohn’s disease were 0.7, 0.9, and 0.7 cases per 100 patient-
years, respectively, in secukinumab-treated patients.
CONCLUSIONS
Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intrave-
nous loading, provided significant reductions in the signs and symptoms of ankylos-
ing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in 
significant improvement only with a higher intravenous loading dose. (Funded by 
Novartis Pharma; ClinicalTrials.gov numbers, NCT01358175 and NCT01649375.)
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Secukinumab in Ankylosing Spondylitis
A nkylosing spondylitis is a chronic, immune-mediated disease that is charac-terized by inflammation and new bone 
formation in the axial skeleton1,2 and that often 
results in progressive, irreversible structural 
damage, disability, deterioration of functioning, 
and a reduced quality of life.3,4 Therapy with 
nonsteroidal antiinflammatory drugs (NSAIDs) 
is often insufficient to control symptoms, and 
there is no evidence that conventional disease-
modifying antirheumatic drugs (DMARDs) are 
efficacious in axial disease.5 Anti–tumor necro-
sis factor (TNF) therapy is currently recommend-
ed for patients with persistent disease activity 
despite conventional treatment.5 In some patients, 
however, such therapy fails to achieve adequate 
disease control or has unacceptable side effects.6-10
Several lines of evidence have identified the 
interleukin-17 pathway as a promising therapeu-
tic target in spondyloarthritis.11-17 Indeed, numbers 
of interleukin-17–producing cells are elevated in 
the circulation and target tissues in patients with 
ankylosing spondylitis.14-18
Secukinumab is a fully human, anti–interleu-
kin-17A monoclonal antibody with proven efficacy 
in psoriasis.19 In a phase 2 study, intravenous 
secukinumab significantly suppressed the symp-
toms of ankylosing spondylitis.9 We present the 
results of two phase 3 trials, MEASURE 1 and 
MEASURE 2, investigating the efficacy and 
safety of secukinumab in patients with active 
ankylosing spondylitis.
Me thods
Study Design and Oversight
These randomized, double-blind, placebo-con-
trolled phase 3 trials, which are ongoing, are 
being conducted at 106 centers across Asia, 
Europe, North America, and South America. 
MEASURE 1 is a 2-year study followed by a 
3-year extension study, and MEASURE 2 is a 
5-year study (see Fig. S1 in the Supplementary 
Appendix, available with the full text of this arti-
cle at NEJM.org). Data from the primary analysis 
at week 16 and the 1-year follow-up analysis (after 
all patients had completed the visit at week 52) 
of both studies are presented here.
Each study was designed by the sponsor, No-
vartis, in collaboration with the authors. The 
institutional review board at each participating 
center approved the protocols. Data were collected 
according to Good Clinical Practice guidelines 
by the study investigators and were analyzed by 
the sponsor. All the authors contributed to the 
interpretation of the data and had access to the 
full data sets. The statistical analyses were per-
formed by statisticians employed by the sponsor 
and were reviewed by all the authors. Agree-
ments between the sponsor and the investiga-
tors included provisions relating to confidential-
ity of the study data. The initial draft of the 
manuscript was written by a medical writer from 
Seren Communications, funded by the sponsor. 
All the authors vouch for the accuracy and com-
pleteness of the data and analyses, as well as for 
the fidelity of this report to the trial protocols, 
which are available at NEJM.org.
Patients
Eligible patients were 18 years of age or older 
and had ankylosing spondylitis fulfilling the 
modified New York criteria.20 They also had a 
score of 4 or higher on the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI; scores 
range from 0 to 10, with higher scores indicat-
ing more severe disease activity)21 and a score for 
spinal pain of 4 cm or more on a 10-cm visual-
analogue scale (with higher numbers indicating 
greater disease activity), despite treatment with 
the maximum doses of NSAIDs that were associ-
ated with an acceptable side-effects profile.
Previous use of DMARDs and anti-TNF agents 
was allowed. Washout periods for these agents, 
other than sulfasalazine and methotrexate, were 
required before initiation of the study treatment. 
Patients previously treated with not more than 
one anti-TNF agent could participate if they had 
an inadequate response to an approved dose for 
3 months or more or had unacceptable side ef-
fects with at least one dose (hereafter collec-
tively referred to as patients with an inadequate 
response to anti-TNF agents). Patients could 
continue to receive the following medications 
at a stable dose: sulfasalazine (≤3 g per day), 
methotrexate (≤25 mg per week), prednisone or 
equivalent (≤10 mg per day), and NSAIDs.
Key exclusion criteria were total spinal anky-
losis, evidence of infection or cancer on chest 
radiography, active systemic infection within 2 
weeks before baseline, and previous treatment 
with cell-depleting therapies or biologic agents 
other than anti-TNF agents. Written informed 
consent was obtained from all the patients.
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Study Procedures
After a 4-week screening period, patients were 
randomly assigned in a 1:1:1 ratio to one of two 
secukinumab groups or the placebo group. In 
MEASURE 1, patients received an intravenous 
loading infusion of secukinumab at a dose of 
10 mg per kilogram of body weight at baseline 
and weeks 2 and 4, followed by subcutaneous 
injections of secukinumab at a dose of 150 mg 
or 75 mg every 4 weeks starting at week 8; pa-
tients in the placebo group were treated accord-
ing to the same schedule of intravenous and 
subcutaneous doses. In MEASURE 2, patients 
received subcutaneous injections of secukinu-
mab (at a dose of 150 mg or 75 mg) or placebo at 
baseline; at weeks 1, 2, and 3; and every 4 weeks 
starting at week 4. At week 16 in both studies, 
patients in the placebo group were randomly 
reassigned to receive secukinumab at a dose of 
150 mg or 75 mg, according to the schedule 
outlined in the Supplementary Appendix. Patients 
who met Assessment of Spondyloarthritis Inter-
national Society 20 (ASAS20) response criteria 
(i.e., improvement of ≥20% and absolute im-
provement of ≥1 unit [on a 10-unit scale] in at 
least three of the four main ASAS domains, with 
no worsening by ≥20% in the remaining do-
main) at week 16 switched to secukinumab at 
week 24 in MEASURE 1. In both MEASURE 1 
and MEASURE 2, patients continued to receive 
subcutaneous secukinumab at a dose of 150 mg 
or 75 mg every 4 weeks from week 16 until the 
end of the study.
Disease activity and efficacy assessments were 
conducted at baseline and throughout the study, 
with key assessments at week 16 (primary analy-
sis) and week 52 (follow-up analysis). Blood 
samples were collected at baseline and immedi-
ately before dose administration at weeks 4, 16, 
24, and 52 for assessment of secukinumab im-
munogenicity with the use of a bridging immu-
noassay (Meso Scale Discovery).22
Outcome Measures
In each study, the primary efficacy end point 
was the proportion of patients who met ASAS20 
response criteria at week 16.23 Secondary end 
points assessed at week 16 included ASAS40 re-
sponse criteria (improvement of ≥40% and abso-
lute improvement of ≥2 units [on a 10-unit scale] 
in at least three of the four main ASAS domains, 
with no worsening in the remaining domain), 
change from baseline in the high-sensitivity 
C-reactive protein (CRP) level, ASAS5/6 response 
(≥20% improvement in five of the six ASAS re-
sponse domains), and changes from baseline in 
the following scores: total BASDAI score, the 
summary score for the physical component in 
version 2 of the Medical Outcomes Study 36-
Item Short-Form Health Survey (SF-36; scores 
range from 0 [maximum disability] to 100 [no 
disability] for individual domains, with a norma-
tive composite summary score of 50),24 and the 
score on the Ankylosing Spondylitis Quality of 
Life (ASQoL) scale (scores range from 0 [best 
quality] to 18 [poorest quality])25; ASAS partial 
remission (a score of ≤2 units in each of the four 
core ASAS domains) and overall safety were also 
assessed.
In each study, a preplanned follow-up analysis 
was performed after all patients had completed 
the visit at week 52. Safety analyses, performed 
with the use of the Common Terminology Crite-
ria for Adverse Events, version 4.03,26 included all 
safety data reported up to the cutoff date after 
all patients had completed at least 52 weeks of 
treatment in either study. Exploratory analyses 
of efficacy were performed at week 52.
Statistical Analysis
We calculated that for MEASURE 1 to have 90% 
power with a 2.5% type I error rate, assuming an 
ASAS20 response rate of 60% for the secukinum-
ab groups and 20% for the placebo group,27 we 
would need to assign at least 39 patients to each 
study group, on the basis of Fisher’s exact test. 
The target population was increased to 116 pa-
tients per group to ensure sufficient safety data, 
providing 94 to 99% power to detect significant 
differences between the secukinumab and pla-
cebo groups for each of the secondary end 
points. We used the same power calculations in 
MEASURE 2. The target sample of 74 patients 
per group provided 99% power to detect signifi-
cant between-group differences for the ASAS20 
response rate and 79 to 99% power for the sec-
ondary end points.
In each study, analyses of primary and sec-
ondary efficacy end points at week 16 included 
all patients according to the treatment assigned 
at randomization. Closed testing procedures28 
were used to maintain a familywise error rate of 
5% across the secukinumab groups and end 
points. The hypotheses for the primary objective 
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in either secukinumab treatment group versus 
the placebo group were tested simultaneously at 
the 0.025 level. On the basis of the rejection of 
one or both of these hypotheses, analysis of the 
secondary end points was completed according 
to a prespecified hierarchy in the sequence de-
scribed in Figure S2 in the Supplementary Ap-
pendix.
The primary end point and other binary end 
points were evaluated by means of logistic re-
gression with treatment and anti-TNF response 
status as factors and weight as a covariate. Miss-
ing values, including those due to discontinuation 
of the study treatment, were imputed as non-
responses. Between-group differences in continu-
ous variables were evaluated with the use of a 
mixed-model repeated-measures (MMRM) ap-
proach, with missing data assumed to be miss-
ing at random and with study group, assessment 
visit, and anti-TNF response status as factors. 
Weight and baseline values of the end points 
were included in the model as continuous co-
variates. Interaction terms included study group 
and baseline value according to assessment visit. 
For the change in the high-sensitivity CRP level, 
the loge ratio of the post-baseline value to the 
baseline value was used to normalize the distri-
bution of the high-sensitivity CRP level at each 
assessment. The end points assessed at week 16 
were analyzed descriptively with the use of ob-
served values from week 20 onward. In a sepa-
rate analysis of these end points from week 20 
onward, missing values for binary variables were 
imputed as nonresponses, and missing values 
for continuous variables were imputed with the 
use of MMRM analysis.
Safety end points were evaluated for all pa-
tients who received at least one dose of the study 
drug; these end points were summarized de-
scriptively. A data and safety monitoring com-
mittee reviewed unblinded safety data at regular 
intervals.
R esult s
Study Participants
In MEASURE 1, from November 9, 2011, through 
January 21, 2013, we randomly assigned 371 
patients to receive an intravenous loading dose 
of secukinumab (10 mg per kilogram) followed 
by subcutaneous secukinumab at a dose of 150 mg 
(125 patients), an intravenous loading dose of 
secukinumab (10 mg per kilogram) followed by 
subcutaneous secukinumab at a dose of 75 mg 
(124), or placebo (122). At week 16, a total of 351 
patients (95%) remained in the study; 20 patients 
discontinued the study for the reasons outlined 
in Figure 1. In MEASURE 2, from October 28, 
2012, through July 29, 2013, we randomly as-
signed 219 patients to receive subcutaneous 
secukinumab at a dose of 150 mg (72 patients), 
subcutaneous secukinumab at a dose of 75 mg 
(73), or placebo (74). At week 16, a total of 200 
patients (91%) remained in the study; 19 patients 
discontinued the study for the reasons outlined 
in Figure 2.
Baseline demographic and disease character-
istics were similar between studies and among 
the groups within each study (Table 1, and Table 
S1 in the Supplementary Appendix). The mean 
time since diagnosis was 6.5 to 8.3 years in 
MEASURE 1 and 5.3 to 7.0 years in MEASURE 2; 
the total BASDAI score was 6.1 to 6.5 and 6.6 to 
6.8, respectively; 69 to 80% and 73 to 79% of 
patients were positive for HLA-B27, respectively; 
and approximately 26 to 39% of patients in each 
group had inadequate responses to anti-TNF 
agents in the two studies. Approximately 3% of 
patients in MEASURE 1 and 2% of those in 
MEASURE 2 had a history of inflammatory 
bowel disease at baseline.
Primary End Point
The primary end point was met in both 
secukinumab groups in MEASURE 1 and in the 
group that received 150 mg of secukinumab 
subcutaneously in MEASURE 2. In MEASURE 1, 
ASAS20 response rates at week 16 were 61% with 
subcutaneous secukinumab at a dose of 150 mg, 
60% with subcutaneous secukinumab at a dose 
of 75 mg, and 29% with placebo (P<0.001 for 
both comparisons with placebo). In MEASURE 2, 
ASAS20 response rates at week 16 were 61% with 
subcutaneous secukinumab at a dose of 150 mg, 
41% with subcutaneous secukinumab at a dose 
of 75 mg, and 28% with placebo (P<0.001 and 
P = 0.10 for comparisons of the higher and lower 
doses, respectively, with placebo) (Fig. 3).
Secondary End Points
In MEASURE 1, all predefined secondary end 
points were met in both secukinumab groups 
(Table 2, and Fig. S5 in the Supplementary Ap-
pendix). ASAS40 response rates at week 16 were 
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42% and 33% in the groups that received subcu-
taneous secukinumab at the higher and lower 
doses, respectively, as compared with 13% in the 
placebo group (P<0.001 for both comparisons 
with placebo) (Fig. 3 and Table 2).
In MEASURE 2, all predefined secondary end 
points except ASAS partial remission were met 
with subcutaneous secukinumab at a dose of 
150 mg; responses with subcutaneous secukinu-
mab at a dose of 75 mg did not differ signifi-
cantly from responses with placebo on the basis 
of hierarchical testing (Table 2, and Fig. S5 in 
the Supplementary Appendix). ASAS40 response 
rates at week 16 were 36% with subcutaneous 
secukinumab at a dose of 150 mg and 26% with 
subcutaneous secukinumab at a dose of 75 mg, 
as compared with 11% with placebo (P<0.001 
and P = 0.10 for comparisons of the higher and 
lower doses, respectively, with placebo) (Fig. 3 
and Table 2).
Long-Term Efficacy
At week 52, a total of 319 patients (86%) re-
mained in MEASURE 1, and 181 patients (83%) 
in MEASURE 2. The clinical responses observed 
at week 16 were maintained through 52 weeks of 
treatment among patients randomly assigned to 
secukinumab at baseline, on the basis of both 
observed data and a more conservative assess-
ment of efficacy in which missing values were 
imputed as nonresponses (Fig. 3, and Fig. S3 and 
Tables S2 and S3 in the Supplementary Appen-
dix). In addition, patients randomly assigned to 
placebo had improvements in ASAS20 response 
rates on switching to secukinumab (Fig. S4 in 
the Supplementary Appendix).
Safety
Adverse events during the placebo-controlled 
periods of both studies are shown in Table 3, as 
well as in Table S4 in the Supplementary Appen-
dix. The incidence of infection was higher with 
secukinumab than with placebo (30% vs. 12% in 
MEASURE 1 and 32% vs. 27% in MEASURE 2).
During the entire safety period of MEASURE 1, 
exposure-adjusted incidence rates of serious 
adverse events were 8.0 and 8.6 events per 100 
patient-years among patients who received at 
least one dose of secukinumab at the higher and 
lower doses, respectively (including patients who 
were randomly assigned to secukinumab at 
baseline and those who switched from placebo 
to active treatment) (Table S5 in the Supplemen-
tary Appendix). The rates of infection were 73.5 
and 59.4 events per 100 patient-years of exposure 
for subcutaneous secukinumab at doses of 150 mg 
and 75 mg, respectively. During the entire safety 
period of MEASURE 2, exposure-adjusted inci-
dence rates of serious adverse events were 6.6 and 
7.7 events per 100 patient-years for subcutaneous 
secukinumab at doses of 150 mg and 75 mg, 
respectively (Table S5 in the Supplementary Ap-
pendix). Incidence rates of infection in the groups 
that received subcutaneous secukinumab at the 
higher and lower doses were 60.5 and 89.1 
events per 100 patient-years of exposure, respec-
tively. No patients in either study discontinued 
treatment because of a serious infection.
Candida infections were reported in three 
patients treated with subcutaneous secukinu-
mab in MEASURE 1 (genital candidiasis in a 
patient receiving the 75-mg dose, oral candidia-
sis in a patient receiving the 75-mg dose, and 
candida thrush infection in a patient receiving 
the 150-mg dose) and in three patients treated 
with subcutaneous secukinumab in MEASURE 2 
(one case of candida infection at the 75-mg dose 
and two cases of oral candidiasis [one each at 
the lower and higher doses]). The pooled expo-
sure-adjusted incidence of candidiasis in secu-
kinumab-treated patients across the two studies 
was 0.9 events per 100 patient-years of exposure 
(Table 4). These events did not lead to study 
discontinuation and resolved spontaneously or 
with standard antifungal treatment.
Grade 3 neutropenia was documented at a 
single visit in each of three patients receiving 
subcutaneous secukinumab at the 75-mg dose in 
MEASURE 1 and in one patient receiving sub-
cutaneous secukinumab at the 150-mg dose in 
MEASURE 2. Grade 4 neutropenia was reported 
in one patient (receiving subcutaneous secu-
kinumab at the 75-mg dose) at a single visit in 
MEASURE 1 (pooled incidence of grade 3 or 4 
neutropenia in the two studies: 0.7 events per 
100 patient-years of exposure [Table 4]). None of 
these events led to treatment interruption or 
discontinuation, and only one grade 3 case was 
associated with infection (a nonserious upper 
respiratory tract infection).
Adjudicated major adverse cardiac events were 
recorded in two patients treated with subcutane-
ous secukinumab in MEASURE 1 (myocardial 
infarction in a patient receiving the 75-mg dose 
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and stroke in a patient receiving the 150-mg 
dose) and in one patient treated with subcutane-
ous secukinumab in MEASURE 2 (fatal myocar-
dial infarction in a patient receiving the 75-mg 
dose). The pooled exposure-adjusted incidence rate 
of adjudicated major adverse cardiac events across 
both studies was 0.4 events per 100 patient-years 
of exposure to secukinumab (Table 4).
Four cancers were reported in MEASURE 1: 
B-cell lymphoma (in a patient receiving subcuta-
neous secukinumab at the 75-mg dose), breast 
cancer (in a patient receiving subcutaneous 
secukinumab at the 150-mg dose), transitional-
cell carcinoma of the bladder (in a patient receiv-
ing subcutaneous secukinumab at the 150-mg 
dose), and lymphoma (in a patient receiving 
placebo). In MEASURE 2, there was a single case 
of malignant melanoma (in a patient receiving 
subcutaneous secukinumab at the 150-mg dose). 
These five events resulted in discontinuation of 
the study treatment.
Crohn’s disease was an adverse event in three 
patients in the group receiving subcutaneous 
secukinumab at a dose of 75 mg in MEASURE 1. 
Two cases were in patients with a history of 
Crohn’s disease, and one was in a patient with 
a history of a polyp and an adenoma in the 
colon; all three cases were nonserious. Crohn’s 
disease was a serious adverse event in two pa-
tients receiving subcutaneous secukinumab in 
MEASURE 2 (one each in the 75-mg and 150-mg 
groups); the patient receiving the lower dose of 
secukinumab was considered to have an exacer-
bation of preexisting Crohn’s disease related to 
the study treatment, and this resulted in discon-
tinuation. The pooled exposure-adjusted incidence 
rate of Crohn’s disease across both studies was 
0.7 events per 100 patient-years of exposure to 
secukinumab (Table 4).
Uveitis was reported in six patients receiving 
secukinumab (five of whom had a history of 
uveitis) and two patients receiving placebo (one of 
whom had a history of uveitis) in MEASURE 1, 
with a single serious case in the 150-mg group 
that resolved and did not lead to discontinuation 
of the study treatment (Table S6 in the Supple-
mentary Appendix). A single case of uveitis was 
reported with subcutaneous secukinumab (at the 
150-mg dose) in MEASURE 2, in a patient with 
no history of uveitis.
There was one death in MEASURE 1 (a sui-
cide in the placebo group) and one death in 
MEASURE 2 (a fatal myocardial infarction in a 
patient receiving 75 mg of secukinumab subcu-
taneously). There were no suicides or adverse 
events related to suicidality among secukinumab-
treated patients.
After treatment was started, antidrug anti-
bodies were detected at week 52 in two patients 
in MEASURE 1 who were receiving subcutane-
ous secukinumab at a dose of 150 mg; neutral-
izing antibodies to secukinumab were detected 
in one of these patients. Neither patient had a 
loss of the ASAS20 response or had any immune-
related adverse events. No antidrug antibodies 
were detected after the start of treatment in 
MEASURE 2.
Discussion
Secukinumab significantly reduced the signs 
and symptoms of ankylosing spondylitis, as com-
pared with placebo, in both phase 3 trials, ex-
tending the positive results of the phase 2 study.9 
An ASAS20 response, the primary end point, 
was achieved in approximately 60% of patients 
in both groups receiving intravenous loading 
followed by subcutaneous secukinumab (150 mg 
or 75 mg) in MEASURE 1 and in the group re-
ceiving 150-mg of subcutaneous secukinumab 
in MEASURE 2, showing that despite the much 
Figure 3 (facing page). Response Rates through Week 
16 (Placebo-Controlled Phase) and through Week 52 
among Patients Randomly Assigned to Secukinumab or 
Placebo at Baseline in MEASURE 1 and MEASURE 2.
Shown are the proportions of patients with Assess-
ment of Spondyloarthritis International Society 20 
(ASAS20) responses (improvement of ≥20% and ab-
solute improvement of ≥1 unit [on a 10-unit scale] in 
at least three of the four main ASAS domains, with no 
worsening by ≥20% in the remaining domain) and the 
proportion with ASAS40 responses (improvement of 
≥40% and absolute improvement of ≥2 units [on a 10-
unit scale] in at least three of the four main ASAS do-
mains, with no worsening in the remaining domain) in 
MEASURE 1 (Panels A and B) and MEASURE 2 (Pan-
els C and D). The predefined statistical hypothesis-
testing hierarchy was designed to maintain the family-
wise type I error rate at 5% across the primary and 
ranked secondary end points. Missing data were im-
puted as nonresponses up to week 16. Observed data 
are presented from week 20 to week 52 (indicated by 
the gray box in each panel). P values at week 16 were 
adjusted for multiple testing. An asterisk denotes 
P<0.05, a dagger P<0.01, and a double dagger P<0.001 
for the comparison with placebo.
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greater exposure conferred by intravenous load-
ing, no incremental increase in efficacy was 
observed, as compared with the subcutaneous 
loading regimen. Benefits over placebo were also 
observed for most of the secondary efficacy end 
points at week 16, including the ASAS40 response, 
high-sensitivity CRP level, ASAS5/6 response, 
and scores on the BASDAI, the physical compo-
nent of SF-36, and the ASQoL scale, and were 
sustained through 52 weeks of therapy. Notably, 
in MEASURE 1 and MEASURE 2, the rates for 
ASAS40 and ASAS5/6 responses, which are based 
on more stringent criteria than those for the 
ASAS20 response, both reached approximately 
60% in the 150-mg dose groups among patients 
who completed 52 weeks of therapy.
Subcutaneous secukinumab at a dose of 
75 mg was shown to be ineffective in MEASURE 2, 
since there were no significant differences in the 
hierarchically tested end points, as compared 
with placebo. These results suggest that the ef-
ficacy of secukinumab at the 75-mg dose in 
MEASURE 1 may have been due to the greater 
exposure at week 16 as a result of the intrave-
nous loading regimen, not to the 75-mg subcu-
taneous maintenance dose. Despite the signifi-
cant results observed with secukinumab at the 
75-mg dose in MEASURE 1, a descriptive analy-
sis showed an increasing dose separation be-
tween the 150-mg and 75-mg treatment groups 
with the use of more stringent response criteria 
(ASAS40 response and ASAS partial remission) 
as time points approached week 52. Moreover, in 
MEASURE 2, subcutaneous secukinumab at the 
150-mg dose showed consistently greater efficacy 
than subcutaneous secukinumab at the 75-mg 
Variable MEASURE 1 MEASURE 2
Secukinumab, 
Pooled Data 
(N = 249)
Placebo 
(N = 122)
Secukinumab, 
Pooled Data 
(N = 145)
Placebo 
(N = 74)
Exposure to study treatment — days 113.2±13.2 109.2±22.7 110.1±15.8 107.6±22.4
Any adverse event — no. of patients (%) 170 (68) 68 (56) 89 (61) 47 (64)
Death — no. of patients (%) 0 1 (<1)† 1 (<1)‡ 0
Serious adverse event — no. of patients (%)‡ 5 (2) 5 (4) 8 (6) 3 (4)
Discontinuation of study treatment because of any adverse event 
— no. of patients (%)
3 (1) 5 (4) 7 (5) 4 (5)
Infection or infestation — no. of patients (%)§ 75 (30) 15 (12) 46 (32) 20 (27)
Common adverse events — no. of patients (%)¶
Nasopharyngitis 30 (12) 9 (7) 14 (10) 3 (4)
Dyslipidemia 24 (10) 6 (5) 2 (1) 1 (1)
Headache 20 (8) 7 (6) 6 (4) 6 (8)
Adverse events of special interest — no. of patients (%)
Candida infection 1 (<1) 0 1 (<1) 0
Crohn’s disease 1 (<1) 0 1 (<1) 0
Major adverse cardiac event, adjudicated 0 0 1 (<1)‡ 0
Neutropenia, grade 3 or 4 0 0 0 0
*  Plus–minus values are means ±SD.
†  The patient had depression and committed suicide.
‡  The patient died from a major adverse cardiac event, adjudicated as myocardial infarction, which was considered to be unrelated to the study 
medication. The patient was a 60-year-old male smoker with multiple baseline cardiac risk factors (elevated hsCRP, lipoprotein A, and low-
density lipoprotein cholesterol levels), who died on day 29 from acute myocardial infarction. An autopsy showed three-vessel cardiac arterio-
sclerosis, cardiac hypertrophy, recurrent anteroseptal myocardial infarction, chronic pulmonary congestion, and emphysema; coronary heart 
disease and nicotine abuse were reported as factors that may have contributed to the infarction.
§  Serious adverse events included deaths.
¶  Common adverse events are those that occurred in at least 5% of patients in the combined secukinumab group in either study during the 
16-week placebo-controlled period. Events are listed according to the preferred terms in the Medical Dictionary for Regulatory Activities.
Table 3. Safety Profile during the 16-Week, Placebo-Controlled Induction Period of the MEASURE 1 and MEASURE 2 Studies.*
n engl j med 373;26 nejm.org December 24, 20152546
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
dose for all primary and secondary end points at 
week 16 (except ASAS partial remission), as well 
as at week 52. Thus, 150 mg administered sub-
cutaneously appears to be the more effective 
dose for secukinumab in patients with ankylos-
ing spondylitis.
Anti-TNF agents are the only approved bio-
logic agents for ankylosing spondylitis, with a 
number of other therapies failing to show ben-
efits.29-33 Although head-to-head trials would be 
required to fully assess the efficacy and safety of 
secukinumab versus TNF-inhibitors, the ASAS20 
Variable MEASURE 1 MEASURE 2
MEASURE 1 and 
MEASURE 2
Any Secukinumab, 
Pooled Data 
(N = 360)
Any Secukinumab, 
Pooled Data 
(N = 211)
Any Secukinumab, 
Pooled Data 
(N = 571)
Exposure to study treatment — days 451.7±146.5 425.8±135.1 442.1±142.8
Any adverse event — no. of patients 
(no. of cases/100 patient-yr)
291 (203.2) 175 (212.9) 466 (206.8)
Death — no. of patients 
(no. of cases/100 patient-yr)†
0 1‡ 1‡
Serious adverse event — no. of patients 
(no. of cases/100 patient-yr)§
35 (8.3) 17 (7.1) 52 (7.9)
Discontinuation of study treatment due to 
adverse event — no. of patients (no. of 
cases/100 patient-yr)†¶
15 9 24
Infection or infestation — no. of patients 
(no. of cases/100 patient-yr)
187 (66.1) 111 (73.7) 298 (68.8)
Common adverse events — no. of patients 
(no. of cases/100 patient-yr)‖
Nasopharyngitis 72 (18.8) 35 (16.3) 107 (17.9)
Headache 39 (9.6) 14 (6.0) 53 (8.3)
Diarrhea 39 (9.4) 14 (5.9) 53 (8.1)
Upper respiratory tract infection 35 (8.4) 17 (7.3) 52 (8.0)
Adverse events of special interest — no. of 
patients (no. of cases/100 patient-yr)
Candida infection 3 (0.7) 3 (1.2) 6 (0.9)
Crohn’s disease 3 (0.7) 2 (0.8) 5 (0.7)
Major adverse cardiac event, adjudicated 2 (0.5) 1 (0.4) 3 (0.4)
Neutropenia, grade 3 or 4 4 (0.9) 1 (0.4) 5 (0.7)
*  Plus–minus values are means ±SD. The reporting period for safety data was the period from baseline to the visit at week 52 
of the last patient enrolled. The placebo group includes all patients who received placebo during the study. The secu-
kinumab groups in this period include any patients who received the stated dose of secukinumab and include patients 
randomly assigned to placebo at baseline who were randomly reassigned to active treatment at week 16 or 24.
†  Exposure-adjusted incidence rates were not calculated for death or discontinuation of study treatment.
‡  The patient died from a major adverse cardiac event, adjudicated as myocardial infarction, which was considered to be 
unrelated to the study medication. The patient was a 60-year-old male smoker with multiple baseline cardiac risk factors 
(elevated hsCRP, lipoprotein A, and low-density lipoprotein levels), who died on day 29 from acute myocardial infarc-
tion. An autopsy showed three-vessel cardiac arteriosclerosis, cardiac hypertrophy, recurrent anteroseptal myocardial 
infarction, chronic pulmonary congestion, and emphysema; coronary heart disease and nicotine abuse were reported 
as factors that may have contributed to the infarction.
§  Serious adverse events included deaths.
¶  An additional three patients discontinued secukinumab because of an adverse event after week 52.
‖  Common adverse events are those that had an exposure-adjusted incidence rate of at least 7.0 cases per 100 patient-
years in the combined secukinumab groups of either study during the entire safety reporting period. Events are listed 
according to the preferred term in the Medical Dictionary for Regulatory Activities.
Table 4. Safety Profile during the Entire Safety Reporting Period in the MEASURE 1 and MEASURE 2 Studies.*
n engl j med 373;26 nejm.org December 24, 2015 2547
Secukinumab in Ankylosing Spondylitis
response rates achieved with secukinumab at 
week 16 in our studies were similar to those 
reported in phase 3 studies of anti-TNF agents 
in which most of the patients had not received 
previous anti-TNF therapy (response rates of 58 
to 64% at weeks 12 to 24),6,7,27,34,35 even though 
30 to 40% of the patients in our studies had had 
no response to previous anti-TNF treatment. 
Thus, secukinumab not only is effective in pa-
tients who have not received TNF agents previ-
ously but also may be effective in patients in 
whom previous anti-TNF treatment failed.
The safety profile of secukinumab in the 
present studies is consistent with that in previous 
studies of secukinumab for ankylosing spondy-
litis and moderate-to-severe plaque psoriasis.9,19 
The incidence of infections or infestations was 
higher with secukinumab than with placebo 
in MEASURE 1. During the entire treatment 
 period, pooled exposure-adjusted incidence rates 
of grade 3 or 4 neutropenia, candida infections, 
and Crohn’s disease were 0.7, 0.9, and 0.7 events 
per 100 patient-years, respectively, among 
secukinumab-treated patients. In MEASURE 1, 
increases in serum cholesterol and triglyceride 
levels were generally mild (grade 1 or 2). Dyslip-
idemia was not evident in MEASURE 2 or in stud-
ies of secukinumab for other indications.9,19,36,37 
Across our two studies, two secukinumab-treat-
ed patients had myocardial infarction and one 
patient had a stroke. One case of myocardial 
infarction, in a patient receiving subcutaneous 
secukinumab at the 75-mg dose in MEASURE 2, 
resulted in death on day 29; the patient was 
found on autopsy to have extensive preexisting 
coronary artery disease. One patient, who was 
receiving placebo, committed suicide. There were 
no suicides or suicidality-related adverse events 
among secukinumab-treated patients in either 
study. The immunogenicity of secukinumab was 
low, and anti-secukinumab antibodies were not 
associated with immune reactions or reduced 
efficacy.
In conclusion, secukinumab showed efficacy 
in key clinical domains of ankylosing spondylitis. 
The results suggest that interleukin-17A plays a 
role in the pathogenesis of ankylosing spondyli-
tis, and they validate inhibition of this cytokine 
as a potential therapeutic approach.
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